Friday, April 25, 2014

Dr. Bill Quick's Posts

Another Me-Too Diabetes Drug

In the field of pharmaceutical medicine, drugs that are the second in their class of medications are frequently called "me-too" (or "me-two") drugs. But what do you call the third and fourth drugs in the same class? Copycats? Hitchhikers? Wishful thinking?   Well, it's happening again: another diabetes drug has been approved by the FDA, and... Read moreChevron

B as in Billion

Takeda Pharmaceuticals U.S.A., manufacturer of the diabetes drug Actos (pioglitazone), just issued a press release today, indicating  that a jury has awarded $6 billion in punitive damages from Takeda and $3 billion from co-defendant, Eli Lilly. That's "B" as in "billion." The jury also awarded $1.475  million in compensatory damages to... Read moreChevron

International Expert Committee Recommends New Way To Diagnose Diabetes

Budapest, Hungary - An international expert committee assembled by the Hungarian Diabetes Association (HDA), International Diabetes Federation (IDF), and European Association for the Study of  Diabetes (EASD) is recommending sneezing as the best test for the diagnosis of diabetes. The recommendations from the Committee, which have not... Read moreChevron

Medtronic Pump Software Flaw

I recently received via snail-mail an "Important Medical Device Safety Information" letter. It's also available on-line.  In the letter, it is stated that "Medtronic has received a small number of reports regarding users who have accidentally programmed the pump to deliver the maximum bolus amount, including one incident that resulted in... Read moreChevron

Too Many Cooks, and a Modest Proposal

The field of diabetes has too many cooks, and as is well known, "Too many cooks spoil the broth." So I'd like to make a modest proposal (below). I'm talking specifically about the fact that there are too many diabetes organizations in the United States speaking for various constituencies.   The latest is another diabetes education... Read moreChevron